GPER1 and melanoma: For the first time, we demonstrate that LNS8801, the enantiomerically pure GPER agonist that is currently in early phase clinical trials for melanoma and other advanced malignancies arising in solid organs (31), effectively inhibits AML in vitro and in an in vivo subcutaneous model.